Drug-coated Balloon Catheter Market Size & Growth Forecast 2026–2035, By Segments (Type, Product, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Drug-coated Balloon Catheter Market size was around USD 783.82 Million in 2025 and is slated to grow at a 8% CAGR from 2026 to 2035, attaining USD 1.69 Billion by 2035. The industry revenue for 2026 is calculated at USD 838.85 million.
Get more details on this report
Request Free Sample ReportDrug-coated Balloon Catheter Market Intelligence Snapshot
Regional Market Dynamics
- North America led the market in 2025 due to established interventional cardiology infrastructure, broad access to catheter-based procedures, experienced physicians, and widespread adoption of advanced vascular technologies.
- Asia Pacific is projected to grow at a 9.04% CAGR, supported by expanding endovascular expertise, greater access to minimally invasive vascular care, and increasing adoption of advanced catheter therapies.
Segment Momentum
- Paclitaxel accounted for 91.21% of the market in 2025 due to its established clinical use, physician familiarity, and broad commercial availability, supporting routine adoption in vascular interventions.
- Peripheral Vascular Disease is the fastest-growing product segment while holding a 69.73% share, driven by strong demand for minimally invasive vascular procedures and continued adoption in routine peripheral interventions.
Market Expansion Drivers
- Rising prevalence of cardiovascular and peripheral artery diseases increasing minimally invasive vascular procedures.
- Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption.
- Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major players in the drug-coated balloon catheter market include Boston Scientific Corporation (United States), Medtronic plc (Ireland), Abbott Laboratories (United States), B. Braun SE (Germany), Koninklijke Philips N.V. (Netherlands), MicroPort Scientific Corporation (China), Lepu Medical Technology (Beijing) Co., Ltd. (China), Meril Life Sciences Pvt. Ltd. (India), Cordis Corporation (United States), Concept Medical Inc. (India).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
The growing burden of cardiovascular disease and peripheral artery disease is shifting more patients into catheter-based treatment pathways, particularly where repeat vessel narrowing, small-vessel disease, or complex lesion profiles make less invasive intervention more attractive than open surgery. This pattern is driving demand for the drug-coated balloon catheter market because physicians increasingly need devices that can restore blood flow while limiting procedural trauma, shortening hospital stays, and reducing recovery complexity for older and higher-risk patients. As case volumes rise in angioplasty suites and vascular centers, procurement increasingly favors tools that fit established minimally invasive workflows and can address restenosis risk without adding permanent implants in every intervention.
Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption
A stronger clinical tilt toward implant-free revascularization is influencing market adoption by positioning drug-coated balloons as a practical option in lesions where leaving no permanent scaffold is clinically advantageous. In the drug-coated balloon catheter market, this preference is especially relevant when physicians want to deliver antiproliferative therapy while preserving vessel flexibility, avoiding the long-term management issues associated with additional stent layers, and keeping future treatment options open. That decision-making dynamic is supporting market expansion in coronary and peripheral interventions where operators are becoming more selective about when a permanent implant is truly necessary.
Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision
AI-enabled imaging guidance is supporting market development by improving lesion assessment, vessel sizing, and procedural planning during endovascular interventions, which makes device selection more targeted and treatment execution more consistent. For the drug-coated balloon catheter market, better imaging precision supports confidence in cases where accurate preparation of the vessel and appropriate balloon deployment are critical to therapeutic performance. As interventional cardiology teams incorporate software-assisted imaging into routine practice, adoption is increasingly shaped by technologies that align with data-guided workflows and help reduce variability in treatment decisions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of cardiovascular and peripheral artery diseases increasing minimally invasive vascular procedures | 2.10% | High | North America, Europe | High | Near Term |
| Expanding clinical preference for implant-free revascularization boosting drug-coated balloon adoption | 1.90% | Moderate | Asia Pacific, North America | High | Mid Term |
| Integration of AI-enabled imaging guidance enhancing interventional cardiology treatment precision | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the largest regional share of the drug-coated balloon catheter market in 2025, backed by established interventional cardiology and peripheral vascular treatment volumes, broad hospital access to catheter-based procedures, and consistent use of advanced device technologies in routine clinical practice. The region’s leadership is strengthened by a mature care delivery environment where specialist centers, outpatient vascular intervention settings, and experienced physician adoption help sustain procedure demand and support continued utilization of drug-coated balloon catheters across complex lesion management.
Asia Pacific is projected to expand at a 9.04% CAGR over the forecast period, with growth in the drug-coated balloon catheter market being fueled by rising access to minimally invasive vascular treatment, expanding interventional capacity across major healthcare systems, and increasing uptake of advanced catheter therapies in high-volume urban hospitals. Adoption is accelerating as more providers build expertise in endovascular procedures and as treatment pathways increasingly favor device options that can address restenosis and lesion complexity within growing cardiovascular and peripheral artery patient populations.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Evidence AdoptionGermany emphasizes clinically validated drug-coated balloon catheter technologies supported by strong hospital purchasing standards. Healthcare providers prioritize devices with proven procedural performance and long-term effectiveness for vascular interventions.
France 🇫🇷
Hospital Treatment OptimizationFrance focuses on optimizing vascular care through selective adoption of drug-coated balloon catheter technologies in hospital settings. Physicians increasingly evaluate devices that support effective restenosis management while aligning with clinical practice standards.
Italy 🇮🇹
Vascular Care ExpansionItaly continues to strengthen the drug-coated balloon catheter market through expanding interventional cardiology and peripheral vascular services. Healthcare providers prioritize dependable device performance and treatment approaches that reduce the need for repeat interventions.
Japan 🇯🇵
Precision Device UtilizationJapan encourages adoption of drug-coated balloon catheters through precision-focused interventional practices and advanced cardiovascular care. Medical institutions value product reliability, procedural efficiency, and compatibility with established treatment protocols.
South Korea 🇰🇷
Innovation-Driven ProceduresSouth Korea integrates drug-coated balloon catheters into modern vascular treatment strategies supported by technologically advanced hospitals. Demand reflects interest in minimally invasive procedures and continuous adoption of next-generation interventional devices.
United States 🇺🇸
Advanced Interventional CareThe U.S. drug-coated balloon catheter market benefits from broad adoption of minimally invasive vascular procedures across specialized healthcare centers. Clinical focus remains on improving treatment outcomes while expanding the use of advanced catheter technologies in peripheral interventions.
Segment Leadership and Growth Trends
Drug-coated Balloon Catheter Market Share (%), Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPaclitaxel held a 91.21% share of the drug-coated balloon catheter market in 2025, reflecting its entrenched position across established clinical use settings and product availability. Its leadership is underpinned by broad familiarity among physicians, deeper commercial penetration, and the fact that paclitaxel-based devices have long formed the core of existing treatment approaches in the drug-coated balloon catheter market. This combination supports continued preference in routine intervention planning, particularly where proven procedural workflows and established usage patterns matter most.
Sirolimus is the fastest-growing segment in the drug-coated balloon catheter market as industry attention increasingly shifts toward alternatives that can expand treatment flexibility and address evolving clinical preferences. Its momentum is being influenced by rising interest in newer drug formulations within interventional practice, especially where buyers and clinicians are more open to evaluating options beyond the dominant paclitaxel category. Relative to established types, sirolimus is gaining traction because growth is coming from adoption expansion rather than replacement alone, giving it stronger room to scale from a smaller installed base.
Product Segment Analysis: Peripheral Vascular Disease (Largest & Fastest-Growing Segment)
Peripheral Vascular Disease accounted for a 69.73% share of the drug-coated balloon catheter market in 2025, and it also remains the fastest-growing product segment as demand continues to concentrate around high-volume vascular intervention needs. Its market leadership is supported by the practical fit of drug-coated balloon catheters in peripheral procedures, where providers require minimally invasive options that align with routine treatment pathways and recurring case volumes. That same procedural relevance is sustaining growth momentum in the drug-coated balloon catheter market, as ongoing utilization in peripheral vascular disease applications creates a larger and more active base for continued adoption than other product areas.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Paclitaxel, Sirolimus | Paclitaxel | Sirolimus |
| Product | Coronary Artery Disease, Peripheral Vascular Disease | Peripheral Vascular Disease | Peripheral Vascular Disease |
| End-use | Hospital, Clinics, Ambulatory Surgical Centers | Hospital | Ambulatory Surgical Centers |
Competitive Landscape and Market Positioning
1. Boston Scientific Corporation (United States)
2. Medtronic plc (Ireland)
3. Abbott Laboratories (United States)
4. B. Braun SE (Germany)
5. Koninklijke Philips N.V. (Netherlands)
6. MicroPort Scientific Corporation (China)
7. Lepu Medical Technology (Beijing) Co. Ltd. (China)
8. Meril Life Sciences Pvt. Ltd. (India)
9. Cordis Corporation (United States)
10. Concept Medical Inc. (India)
The drug-coated balloon catheter market is advancing through continuous innovation in minimally invasive treatment technologies. R&D investments are focused on improving drug delivery efficiency and procedural outcomes. New product introductions are enhancing clinical precision and patient recovery performance. Collaborative initiatives are also supporting faster clinical adoption and technological refinement.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Teleflex Incorporated | Oct-25 | Teleflex Incorporated entered a definitive agreement to acquire substantially all of BIOTRONIK’s Vascular Intervention business for approximately EUR 760 million. The transaction strengthens Teleflex’s interventional portfolio, expanding its global footprint in vascular access and drug-coated balloon-adjacent technologies used in minimally invasive cardiovascular procedures. |
| BrosMed | Feb-25 | BrosMed entered a strategic collaboration with Cordis to commercialize the VaSecure next-generation drug-coated balloon in China. The partnership focuses on strengthening distribution channels, accelerating clinical adoption, and expanding patient access to advanced drug-coated balloon technologies within China’s growing interventional cardiovascular market. |
| Cordis | Oct-23 | Cordis completed the acquisition of MedAlliance, integrating SELUTION SLR sustained sirolimus drug-eluting balloon technology into its cardiovascular portfolio. The acquisition enhances Cordis’s interventional product offering and strengthens its competitive position in drug-coated balloon and drug-eluting balloon technologies for coronary and peripheral artery disease treatment. |
| Boston Scientific Corporation | Feb-22 | Boston Scientific Corporation acquired Baylis Medical Company, expanding its transseptal access and catheter-based intervention portfolio. The acquisition enhances its structural heart and vascular intervention capabilities by integrating guidewires, sheaths, and balloon dilators, strengthening its position in minimally invasive cardiovascular procedures and related delivery technologies. |
| B. Braun Interventional Systems Inc. | Mar-21 | B. Braun Interventional Systems collaborated with Infraredx, a Nipro company, to conduct clinical trials for its SeQuent Please ReX drug-coated PTCA balloon catheter. The partnership supported regulatory advancement efforts, contributing to FDA approval pathways and strengthening long-term collaboration between B. Braun and Nipro in coronary artery disease intervention technologies. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Drug-coated Balloon Catheter Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Drug-coated Balloon Catheter Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much is the drug-coated balloon catheter market worth?
How is the drug-coated balloon catheter industry projected to perform over the next decade?
How is the shift toward implant-free revascularization shaping clinical adoption in the drug-coated balloon catheter market?
What is driving the expansion of minimally invasive vascular procedures in the drug-coated balloon catheter market?
Why does paclitaxel remain the leading type in the drug-coated balloon catheter market?
Which product segment is growing the fastest in the drug-coated balloon catheter market?
Why does North America lead the drug-coated balloon catheter market?
What is driving growth in the drug-coated balloon catheter market across Asia Pacific?
What are the key competitors in the drug-coated balloon catheter landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization